Executive summary Liver diseases have become a major health threat across Europe, and
the face of European hepatology is changing due to the cure of viral hepatitis C and the …

Primary liver cancer—including hepatocellular carcinoma (HCC) and intrahepatic
cholangiocarcinoma (ICC)—incidence is increasing and is an important source of cancer …

The presence of an intrahepatic cholangiocarcinoma (iCCA) in a cirrhotic liver is a
contraindication for liver transplantation in most centers worldwide. Recent investigations …

Background At present, intrahepatic cholangiocarcinoma is a contraindication for liver
transplantation. However, previous studies in this field did not preselect patients on the basis …

Cholangiocarcinoma is an aggressive biliary neoplasm lacking effective therapeutic agents.
Immunotherapies targeting the PD-L1/PD-1 immune checkpoint have shown encouraging …

Cholangiocarcinoma is an aggressive malignancy with poor overall survival. Approximately
15% of intrahepatic cholangiocarcinomas contain FGFR alterations. Infigratinib is an oral …

Intrahepatic cholangiocarcinoma (ICC) is the second most common malignancy arising from
the liver. ICC makes up about 10% of all cholangiocarcinomas. It arises from the peripheral …

Background Immunotherapy has demonstrated a limited clinical efficacy in approximately
5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response …

Background Lymphadenectomy ensures accurate staging for patients with intrahepatic
cholangiocarcinoma, especially for those without preoperatively suspected positive lymph …

Background We sought to evaluate and validate the 8th edition of the AJCC classification
using a multi‐institutional cohort of patients with intrahepatic cholangiocarcinoma (ICC) …